|
Symbol
|
PMWLTQ | Z093XZ | OCJRCH | IHTEFG | HZJEFG | RMBFAV | OOIRCH | RLOALV | Z09YGZ | PBURCH | RMA3QV | RMBRKV | ERORCH | PEIRCH | ABMUTQ | PJIRCH | AZFBIL | PRZRCH | Z0ARNZ | CQWBKB |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Worst of Callable Reverse Convertible | Reverse Convertible | Reverse Convertible | Multi Vonti | Worst of Callable Reverse Convertible | Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Worst of Callable Reverse Convertible | Multi Vonti | Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Multi Reverse Convertible | Worst of Callable Reverse Convertible | Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible |
|
Sous-jacent
|
Amgen Inc. / Lonza Group N / Novartis Sandoz Basket / Pfizer Inc. / Roche AG | Lonza Group N / Tecan Group AG / Ypsomed Hldg. AG | Kühne & Nagel Intl. AG / Lonza Group N / Sandoz Group AG | Compagnie Financière Richemont SA / Lonza Group N / Sonova Hldg. AG / Swiss RE AG / Swisscom N | Lonza Group N / Roche GS / Sika AG | Kühne & Nagel Intl. AG / Lonza Group N / Sika AG | Holcim/Amrize Basket / Kühne & Nagel Intl. AG / Lonza Group N / VAT Group | Lonza Group N | Compagnie Financière Richemont SA / Lonza Group N / Schindler PS / Sika AG | Alcon / Lonza Group N / Sandoz Group AG | Alcon / Lonza Group N / Novartis AG / Roche AG / Sandoz Group AG | Bucher Industries AG / Lonza Group N / Sika AG | BKW AG / Kühne & Nagel Intl. AG / Lonza Group N | Lonza Group N / Novartis AG / Roche AG / Sandoz | Clariant AG / Comet Hldg. AG / Lonza Group N / OC Oerlikon N / Swatch Group I | Bachem Hldg. AG / Lonza Group N / Ypsomed Hldg. AG | Companie Financière Richemont SA / Julius Baer Group / Lonza Group N | Lonza Group N / Swiss Life Hldg. N / Swiss RE AG | Holcim/Amrize Basket / Lonza Group N / Sandoz Group AG | Lonza Group N / Novartis N / Roche GS / Straumann Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
09.02.2026 | 19.02.2026 | 08.04.2026 | 28.06.2029 | 02.11.2026 | 13.07.2026 | 15.01.2026 | 30.12.2025 | 27.08.2027 | 21.07.2026 | 09.11.2026 | 05.11.2026 | 06.11.2026 | 11.11.2026 | 20.12.2029 | 16.06.2026 | 04.02.2026 | 24.02.2027 | 25.08.2026 | 13.03.2028 |
| Ratio | - | - | - | - | - | - | - | 0,09944 | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
56,45 | 357,44 | 414,6035 | 325,00 | 182,298 | 214,60 | 171,665 | 497,20 | 160,356 | 367,64 | 384,30 | 197,80 | 141,44 | 384,30 | 346,32 | 44,0525 | 46,92 | 534,80 | 463,386 | 200,5388 |
| rendement max. p.a. | - | 640,33% | 39,89% | - | - | 63,81% | 14,45% | - | 13,89% | 7,73% | 7,43% | 27,90% | 5,65% | 4,58% | 13,14% | 8,18% | -0,08% | 5,51% | 6,55% | 7,19% |
| Demande | 96,05 | - | - | - | 86,77 | 77,10 | 99,55 | 99,70 | - | - | 97,70 | 91,90 | - | 99,58 | 77,40 | 97,70 | 101,11 | 97,79 | - | 94,97 |
| Offre | - | - | - | - | - | 77,90 | 100,35 | 100,30 | - | - | 98,50 | 92,70 | - | 100,38 | 78,18 | 98,50 | 101,92 | 98,59 | - | 95,77 |